Format

Send to

Choose Destination
Vaccine. 2015 Apr 21;33(17):2015-21. doi: 10.1016/j.vaccine.2015.03.012. Epub 2015 Mar 14.

Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.

Author information

1
Faculty of Medicine and Institute for Life Sciences, University of Southampton, UK.
2
Faculty of Medicine and Institute for Life Sciences, University of Southampton, UK; Southampton NIHR Respiratory Biomedical Research Unit, University Hospital Southampton Foundation NHS Trust, Southampton, UK.
3
Pathogen Genomics, Wellcome Trust Sanger Institute, UK.
4
Faculty of Medicine and Institute for Life Sciences, University of Southampton, UK; Southampton NIHR Respiratory Biomedical Research Unit, University Hospital Southampton Foundation NHS Trust, Southampton, UK; NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton Foundation NHS Trust, Southampton, UK.
5
Faculty of Medicine and Institute for Life Sciences, University of Southampton, UK; Southampton NIHR Respiratory Biomedical Research Unit, University Hospital Southampton Foundation NHS Trust, Southampton, UK. Electronic address: s.c.clarke@soton.ac.uk.

Abstract

The seven-valent pneumococcal conjugate vaccine (PCV7) was added to the UK national immunisation programme in September 2006. PCV13 replaced PCV7 in April 2010. As carriage precedes disease cases this study collected carried pneumococci from children each winter from 2006/7 to 2010/11 over PCV introduction. Conventional microbiology and whole genome sequencing were utilised to characterise pneumococcal strains. Overall prevalence of pneumococcal carriage remained stable. Vaccine serotypes (VT) decreased (p<0.0001) with concomitant increases in non-vaccine serotypes (NVT). In winter 2010/11 only one isolate of PCV7 VT was observed (6B). PCV13 unique VTs decreased between winters immediately preceding and following PCV13 introduction (p=0.04). Significant decreases for VTs 6B, 19F, 23F (PCV7) and 6A (PCV13) and increases for NVT 21, 23B, 33F and 35F were detected. The serotype replacement was accompanied by parallel changes in genotype prevalence for associated sequence types with clonal expansion contributing to replacement. By winter 2010/11, serotype coverage of PCV7 and PCV13 was 1% and 11% respectively. VT replacement was observed for PCV7 and PCV13 serotypes. Conjugate vaccine design and use requires continuous monitoring and revision.

KEYWORDS:

Next generation sequencing; Pneumococcal vaccines; Serotype replacement; Streptococcus pneumoniae; Whole genome

PMID:
25776920
PMCID:
PMC4392391
DOI:
10.1016/j.vaccine.2015.03.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center